Avantor, Inc. research snapshot
AVTR AI stock analysis reads Avantor as a mission-critical life sciences and advanced technology consumables and services provider with recurring revenue from installed base and strong free cash flow generation, but with elevated debt from the VWR acquisition, a large impairment charge in Q3 2025, mostly Hold analyst consensus, and limited near-term catalysts. At the July 12, 2026 data cutoff, AVTR traded near $10.51 with a verified market capitalization near $7.18 billion. This page uses scenario ranges and source checks, not a certain stock price prediction, and is for informational use only.
Current price
$10.51
Market cap
$7.18 billion
AI score
52 / 100
Rating
Turnaround life sciences supplier, high debt but strong FCF and recurring revenue base
Trend status
Recovered 45% from March 2026 lows near $7.26 but still 34% below 52-week highs of $15.93
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Avantor sells consumables, chemicals, equipment, and services that labs, biopharma manufacturers, and advanced technology producers buy repeatedly. Over 70% of revenue is recurring from consumables and services. | Medium-high |
| Moat | Switching costs from validated workflows, regulated method familiarity, and GMP-grade supply agreements. Brand from J.T. Baker heritage. Scale in distribution through VWR network. But moat is narrower than Thermo Fisher or Danaher. | Medium |
| Management | CEO Emmanuel Ligner has led the company since 2017 through the VWR merger, IPO, COVID surge, and post-pandemic normalization. Capital allocation focused on debt reduction. Management holds small equity stake. | Medium |
| Financial trend | Revenue has declined from $7.6B (FY2022 peak) to ~$6.6B TTM as COVID-related demand normalized. A $711.8M goodwill impairment in Q3 2025 produced a large GAAP loss. FCF remains positive at ~$489M TTM. Net debt is ~$3.5B. | Medium |
| Valuation | Forward P/E of 12.4x and EV/EBITDA of ~11x (using adjusted EBITDA). Price/Sales of 1.0x. Cheap vs Thermo Fisher (25x) and Danaher (28x) but discount reflects higher leverage and slower growth. | Medium |
| Technical trend | Stock broke above the 50-day MA in June 2026 and is testing the 200-day MA near $11. RSI is neutral. Volume was elevated on the July 9 gap up. Resistance at $11 (200-MA) and $12 (prior support). Support at $9 and $7.26 (52-week low). | Medium |
| Risk level | Elevated. Large debt ($3.8B) limits financial flexibility. Opioid controversy and regulatory risk. Customer destocking cycles. Biotech funding environment affects capital spending. High EV/EBITDA suggests limited margin of safety for debt service. | Medium-high |
| AI confidence | Medium. Data quality is good for reported financials but impaired earnings and Hold consensus reduce conviction on forward price direction. | Medium |
| Investment certainty | Medium-low. The business is real and recurring, but the debt overhang and uncertain organic growth trajectory make it a show-me story. | Medium-low |
AVTR AI stock forecast
AVTR price scenarios depend on three factors: (1) whether organic revenue growth re-accelerates as biotech funding improves and destocking ends, (2) whether the company can reduce net leverage from the current ~3.5x EBITDA to a more comfortable 2.5x, and (3) whether a strategic event (takeover or large divestiture) changes the equity story.
$15 - $23
Biotech funding recovers sharply, organic growth reaches 4-5%, debt is reduced to 2.5x EBITDA within 18 months, and AVTR is re-rated closer to peer multiples (15-18x forward earnings). A takeout by a larger peer at a premium would also reach this range.
$9 - $15
Revenue grows 1-2% organically, debt is gradually reduced, FCF stays near $450-500M annually, and the stock trades at 12-14x forward earnings. This is roughly in line with the current analyst consensus range ($7-$11 targets).
$5 - $9
Biotech funding remains constrained, customer destocking persists, organic revenue declines, and debt service costs consume an increasing share of FCF. A recession would pressure lab spending across the sector, and AVTRs leverage would amplify the downside.
AVTR AI technical analysis
As of July 12, 2026, AVTR shows an improving short-term momentum picture after bouncing from the March 2026 low near $7.26. The stock gapped up on July 9 following an analyst upgrade and is now testing its 200-day moving average near $11.00. Volume patterns suggest accumulation, but resistance levels overhead are well-defined.
| Level | Value | Why it matters |
|---|---|---|
| Support 1 | $9.00 | Prior resistance from October 2025, now a support level. A break below would signal the rally has failed. |
| Support 2 | $7.26 | 52-week low from March 2026. A break below this level would open a test of the 2020 IPO low zone near $5.00. |
| Resistance 1 | $11.00 | 200-day moving average. The stock has not closed materially above this level since August 2025. |
| Resistance 2 | $12.00 | Prior support zone from late 2025 that broke down in January 2026. Now acts as overhead supply. |
| Resistance 3 | $15.93 | 52-week high. A breakout above this level would require a fundamental catalyst. |
| 50-day MA | $9.20 | AVTR is well above its 50-day MA, a short-term bullish signal. |
| 200-day MA | $11.00 | The 200-day MA is the key inflection point. A decisive close above could shift the medium-term trend to bullish. |
| RSI (14) | 58 | Neutral. Not overbought, leaving room for further upside in the short term. |
AVTR AI trading strategy
This AVTR AI trading strategy framework provides guidelines and risk controls. It is not personalized investment advice. The high debt load and mostly Hold analyst consensus suggest a patient approach with clear invalidation levels.
Enter on a confirmed close above the 200-day MA ($11.00) with volume confirmation above the 50-day average (~9.6M shares). Target the $12-$13 zone. Trail stop at $10.00.
Risk: 9-10% per position. Invalidation: Reversal below $9.50 within two weeks of entry.
Buy near $9.00 support with a stop at $8.50. Target $10.50-$11.00 for a quick mean-reversion trade. This works best when AVTR is oversold on the daily RSI (below 30).
Risk: 5-6% per position. Invalidation: Close below $8.50, which would suggest the support has broken.
A longer-term framework: accumulate on weakness if the company demonstrates consistent debt reduction. Monitor quarterly FCF and net leverage ratio. Add to position if net leverage drops below 3.0x EBITDA.
Scale in with 1/3 position size. Invalidation: net leverage above 4.0x or an unexpected dividend/capital raise that dilutes equity.
Investment research summary
Avantor sells 4 million+ products including lab chemicals, consumables, equipment, and services to biopharma, healthcare, education, and advanced technology customers. Labs reorder consumables regularly, creating a recurring revenue stream that accounts for over 70% of total sales.
Moat is moderate and comes from validated workflows (customers cannot easily swap chemicals mid-process), GMP-grade supply certifications, broad SKU coverage through VWR distribution, and brand heritage from J.T. Baker (founded 1904). However, moat is narrower than top-tier peers like Thermo Fisher.
The thesis fails if (1) biotech funding stays depressed and lab spending contracts further, (2) the debt burden prevents strategic flexibility or forces an equity dilution, (3) the opioid controversy produces fines or reputational damage that loses customer trust, or (4) a recession sharply reduces lab consumables demand.
CEO Emmanuel Ligner has been in place since 2017. Key achievements include the VWR acquisition (2017), the 2019 IPO, and navigating the COVID demand surge. Management holds a small direct equity stake. Board includes representatives from New Mountain Capital (10% owner) and independent directors.
Avantor serves end markets (biopharma R&D, healthcare, advanced tech) that grow with long-term secular trends: aging population, biologics adoption, cell and gene therapy, and semiconductor materials complexity. However, near-term biotech funding has been constrained by higher interest rates.
At $10.51, AVTR trades at 1.0x sales, 1.2x book, and 12.4x forward earnings. The three-scenario model estimates a base case target of ~$15.00 (42% upside) within 3 years assuming 8% EPS growth and a 14x PE. The bear case target of ~$7.30 implies 31% downside. The bull case reaches ~$23.30.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $10.51 | Yahoo Finance | July 9, 2026 |
| Market cap | $7.18 billion | Yahoo Finance + verification tool | July 9, 2026 |
| Enterprise value | $10.71 billion | Yahoo Finance | July 9, 2026 |
| Revenue (TTM) | $6.55 billion | Yahoo Finance / Google Finance | July 10, 2026 |
| Net income (TTM) | -$551.4 million | Yahoo Finance | July 9, 2026 |
| EPS (TTM) | -$0.81 | Yahoo Finance | July 9, 2026 |
| Free cash flow (TTM) | $489 million | Yahoo Finance | July 9, 2026 |
| Total cash (MRQ) | $279.3 million | Yahoo Finance | July 9, 2026 |
| Total debt | ~$3.81 billion (estimated) | Calculated from EV = Market Cap + Debt - Cash | July 9, 2026 |
| Shares outstanding | 682.8 million | Google Finance / verification tool | July 10, 2026 |
| Forward P/E | 12.44x | Yahoo Finance | July 9, 2026 |
| Price/Sales (TTM) | 1.01x | Yahoo Finance | July 9, 2026 |
| Price/Book (MRQ) | 1.19x | Yahoo Finance | July 9, 2026 |
| EV/EBITDA (TTM) | ~11.1x (using adjusted EBITDA) | Calculated from EV + quarterly EBITDA | July 10, 2026 |
| 52-week range | $7.26 - $15.93 | Yahoo Finance | July 9, 2026 |
| Beta | 0.94 | Yahoo Finance | July 9, 2026 |
| Analyst consensus | Hold (0 Buys, 8 Holds, 2 Sells) | Google Finance | July 10, 2026 |
| Average price target | $9.00 | Google Finance / 10 analysts | July 10, 2026 |
This AVTR AI stock analysis page is for informational and educational use only. It does not constitute investment advice, a recommendation, or an offer to buy or sell any security. All forecasts, scenarios, and technical levels are based on publicly available data as of the data cutoff date and may be inaccurate or outdated. Past performance is not indicative of future results. Investing in stocks involves risk, including the potential loss of principal. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
